NCT00001026View on ClinicalTrials.gov

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 1994

Conditions
HIV Infections
Interventions
BIOLOGICAL

gp160 Vaccine (Immuno-AG)

BIOLOGICAL

rgp120/HIV-1IIIB

BIOLOGICAL

rgp120/HIV-1MN

BIOLOGICAL

rgp120/HIV-1 SF-2

BIOLOGICAL

HIVAC-1e

Trial Locations (2)

14642

Univ. of Rochester AVEG, Rochester

98144

UW - Seattle AVEG, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001026 - A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals | Biotech Hunter | Biotech Hunter